Literature DB >> 22633079

The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans.

Gianni Biolo1, Paola Secchiero, Sara De Giorgi, Veronica Tisato, Giorgio Zauli.   

Abstract

BACKGROUND & AIMS: Although decreased levels of circulating TRAIL have been associated to cardiovascular risk and overall mortality, the mechanisms controlling TRAIL levels in physiopathological conditions are currently unknown. The aim of the present study was to investigate whether changes in the energy intake and insulin sensitivity may influence circulating TRAIL, and to analyze potential relationships between circulating TRAIL and changes in fat mass in healthy subjects receiving hypocaloric or hypercaloric diets.
METHODS: Three distinct groups of participants were studied, at the end of a 14-day (n = 9), 35-day (n = 30) or 60-day (n = 16) period of experimental bed rest to induce insulin resistance and during controlled ambulation, after receiving eucaloric, hypocaloric or hypercaloric diets.
RESULTS: After bed rest conditions, energy restriction significantly decreased circulating TRAIL, while overfeeding significantly increased TRAIL levels with respect to eucaloric control subjects. Moreover, a positive correlation was found between levels of circulating TRAIL and energy intake as well as between circulating TRAIL and energy balance, as determined by changes in fat mass in these subjects.
CONCLUSIONS: Circulating levels of TRAIL exhibit a clear-cut positive correlation with the energy intake and balance in healthy subjects during experimental physical inactivity.
Copyright © 2012 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633079     DOI: 10.1016/j.clnu.2012.04.016

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  6 in total

1.  TRAIL (TNF-related apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors.

Authors:  Verena Zoller; Jan-Bernd Funcke; Michaela Keuper; Muad Abd El Hay; Klaus-Michael Debatin; Martin Wabitsch; Pamela Fischer-Posovszky
Journal:  Cell Death Dis       Date:  2016-10-13       Impact factor: 8.469

Review 2.  TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?

Authors:  Stella Bernardi; Rebecca Voltan; Erika Rimondi; Elisabetta Melloni; Daniela Milani; Carlo Cervellati; Donato Gemmati; Claudio Celeghini; Paola Secchiero; Giorgio Zauli; Veronica Tisato
Journal:  Clin Sci (Lond)       Date:  2019-05-16       Impact factor: 6.124

3.  TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma.

Authors:  M Keuper; I Wernstedt Asterholm; P E Scherer; M-A Westhoff; P Möller; K-M Debatin; G Strauss; M Wabitsch; P Fischer-Posovszky
Journal:  Cell Death Dis       Date:  2013-01-24       Impact factor: 8.469

4.  Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry.

Authors:  Carlo Cervellati; Paola Secchiero; Gloria Bonaccorsi; Claudio Celeghini; Giorgio Zauli
Journal:  Mediators Inflamm       Date:  2014-05-21       Impact factor: 4.711

5.  Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women.

Authors:  Veronica Tisato; Paola Secchiero; Gloria Bonaccorsi; Carlo Bergamini; Pantaleo Greco; Giorgio Zauli; Carlo Cervellati
Journal:  Mediators Inflamm       Date:  2017-09-05       Impact factor: 4.711

6.  Effects of Hypoxia and Bed Rest on Markers of Cardiometabolic Risk: Compensatory Changes in Circulating TRAIL and Glutathione Redox Capacity.

Authors:  Gianni Biolo; Filippo G Di Girolamo; Adam McDonnell; Nicola Fiotti; Filippo Mearelli; Roberta Situlin; Arianna Gonelli; Barbara Dapas; Mauro Giordano; Mitja Lainscak; Gabriele Grassi; Giorgio Zauli; Paola Secchiero; Igor Mekjavic
Journal:  Front Physiol       Date:  2018-07-30       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.